Abstract：Objective: To analyze the efficacy of warfarin anticoagulation therapy in patients with non valvular atrial fibrillation under the guidance of clinical pharmacists. Methods: 91 patients with non-valvular atrial fibrillation who received therapy from January 2014 to June 2017 in our hospital, according to different treatment methods. All the patients were divided into 47 control groups and 44 research groups. The control group was treated with traditional warfarin, and the research group was given warfarin under the guidance of clinical pharmacist. then treatment compliance, international standardized ratio (INR), endothelial function, fibrinolytic index, and adverse reactions between two group was compared. Results: After treatment, the therapeutic compliance in the research group was better than that of the control group, with statistically significant difference (P<0.05). the INR compliance rate in research group was higher than the control group (P<0.05). Before treatment,the endothelin 1 (ET-1), circulating endothelial cells (CEC) in two group was no difference (P>0.05), after treatment, the above indicators in research group was lower than the control group, with statistically significant difference (P<0.05). plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA) and D-dimer (D-D) in research group were lower than the control group (P<0.05). Complication rate in research group was lower than that in the control group (P<0.05). Conclusion: Non-valvular AF patients with clinical pharmacist guidance warfarin anticoagulant therapy can change the patient's cognitive and behavioral status, improve their treatment compliance and INR compliance rate, reduce the risk of warfarin anticoagulation.
[1] Kumar D, Kumar S, Desai N. Role of transesophageal echocardiography during left atrial appendage occlusion device closure in a patient with non-valvular atrial fibrillation and angiodysplasia of the colon [J]. Ann Card Anaesth, 2018, 21 (1): 88 ~91. [2] 王志尊,王伟,杜昕,等.非瓣膜病心房颤动患者华法林长期抗凝治疗的依从性[J].中华心血管病杂志,2017,45(11):920~923. [3] 曾颖,袁进,李小芳,等.心血管门诊患者华法林抗凝治疗现状调研分析[J].岭南心血管病杂志,2017,23(5):566~570. [4] 王佳丽,高鹏,范静波,等.抗凝门诊中非瓣膜病心房颤动卒中高危人群服用华法林的影响因素分析[J].中国介入心脏病学杂志,2016,24(9):487~492. [5] 张薇,田国祥,夏常泉,等.老年心房纤颤患者长期服用华法林的剂量、INR及影响因素[J].中国循证心血管医学杂志,2015,7(4):448~450. [6] 中国老年学学会心脑血管专业委员会.中国房颤抗凝的现状与未来[J].中国心血管病研究,2014,12(9):769~770. [7] 周立英,郭自同,姚娟.2种治疗方法对非瓣膜病心房颤动患者抗凝的比较研究[J].新疆医科大学学报,2016,39(9):1103~1105. [8] Gilligan AM, Franchino-Elder J, Song X, et al. Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosednon-valvular atrial fibrillation newly treated with oral anticoagulants[J]. Curr Med Res Opin,2018,34(2):285~295. [9] 周扬. 低抗凝剂量华法林与阿司匹林对老年非瓣膜病房颤患者疗效及安全性的比较[J].中华全科医学,2015,13(11):1898~1900. [10] 杜晓明,陈闯,秦炎寒,等.非瓣膜性房颤患者华法林应用调查分析[J].中国药学杂志,2015,50(22):2000~2003. [11] 胡勇平.基层医院临床药师指导华法林抗凝治疗非瓣膜病心房颤动与传统治疗的差异[J].中国医院药学杂志,2017,37(3):294~296. [12] 武云涛,陈艳梅,田国祥,等.华法林低强度抗凝治疗高龄非瓣膜病性心房颤动长期随访研究[J].中国循证心血管医学杂志,2017,9(4):430~432. [13] 孙艺红.心房颤动的抗凝治疗及进展[J].中华全科医师杂志,2016,15(10):740~743. [14] Neumann P, Jae N, Knau A, et al. The lncRNA GATA6-AS epigenetically regulates endothelial gene expression via interaction with LOXL2 [J]. Nat Commun, 2018, 9 (1): 237~245. [15] Corbalan R, Conejeros C, Rey C, et al. Features, management and prognosis of chilean patients with non valvular atrial fibrillation: GARFIELD AF registry[J]. Rev Med Chil,2017,145(8):963~971.
2018, Vol. 24 
冀公网安备13080202000677号